Brain Matters
Neuroscience and mental health advancements from The Florey Spring 2026
Turning back the clock on Parkinson’s disease Page 3
Printed on 100% recycled paper
Director’s update Welcome to the latest issue of Brain Matters – a celebration of The Florey’s research achievements. Below you can read about the tremendous success of the Australian Epilepsy Project (AEP) in securing an additional funding commitment from the Federal Government. This support will help improve epilepsy diagnosis and management and advance digital health innovation. We are also pleased to share news of an innovative research project that
aims to treat Parkinson’s disease using stem cell therapy (see p. 3). You can also read about how our researchers are growing ‘mini brains’ in the lab to help them better understand and treat multiple sclerosis (see p. 4). Earlier this year, many students and staff members of The Florey took part in the Conquer Cancer relay – a monthlong, non-stop running event – to raise money for brain cancer research (see p. 9). Community fundraising efforts and the generosity of our donors is what enables our researchers to continue their important work.
We thank you for your ongoing interest in our research and for your support. We hope you enjoy reading this edition of Brain Matters and look forward to bringing you more exciting news from The Florey in the future.
Professor Peter van Wijngaarden Executive Director, The Florey
Major support for brain health Australians living with epilepsy and other neurological and mental health conditions will benefit from faster diagnosis and treatment, after the Federal Government committed an additional $30 million to support the expansion of a leading brain health research project. The Australian Epilepsy Project (AEP), a flagship Florey research initiative, was established in 2021 with an initial $30 million from the Medical Research Future Fund (MRFF) – the single largest government investment into epilepsy research in Australia. Using artificial intelligence, the AEP has created an innovative platform bringing together advanced MRI scans, genetic analysis and cognitive testing to offer patients a new and improved standard of care for epilepsy. The additional funding over four years will enable the AEP to: • Scale its reach across the health system to establish its leading standard of care for epilepsy across Australia; • Investigate digital solutions for brain disorders beyond epilepsy to benefit the millions of Australians living with neurological and mental health conditions; and
Federal Health Minister Mark Butler with the AEP team and Florey executives
• Develop its technical capability and products in readiness for commercialisation and international market expansion to benefit the Australian economy. Chief Investigator and Florey Deputy Director, Professor Graeme Jackson, said digital technologies and AI can translate research into new, optimised models of healthcare at population scale. “This brings the highest standard of care to the whole population, with particular impact for rural and regional Australia. This is the future,”
Professor Jackson said. “AEP has successfully established a high standard of care for epilepsy, bringing advanced research to clinical impact in a platform model that connects patients with their doctors and ongoing research.” The Federal Health Minister, Mark Butler, last year hailed the AEP as “exemplar” of what the MRFF can achieve. Since its development, the AEP has connected more than 2,100 patients with more than 160 neurologists across Australia.
Acknowledgement of Country The Florey acknowledges the Traditional Owners of the land on which we work, the Wurundjeri people of the Kulin Nation. We pay our respects to their Elders past, present and emerging. The Florey is committed to the aims, principles and actions of marra ngarrgoo, marra goori: The Victorian Aboriginal Health, Medical and Wellbeing Research Accord. 2
Brain Matters Spring 2026
Using stem cells to repair Parkinson’s damage In recent years, stem cell therapy has emerged as a promising new approach to replace lost brain cells in people living with Parkinson’s disease, but transplant rejection has been an obstacle. A new five-year $4.6 million research program, supported by the Australian Government’s Medical Research Future Fund, will test whether an innovative stem cell therapy can reverse the devastating effects of Parkinson’s disease. Developed by regenerative medicine company iCamuno Biotherapeutics, the therapy involves the transplantation of dopamine-releasing neurons with the potential to repair brain damage caused by Parkinson’s disease without the need for long-term immunosuppression, a key limitation of other stem cell approaches. Dopamine-producing neurons in the brain progressively die in Parkinson’s disease, leading to loss of movement and other debilitating symptoms. The Florey’s Deputy Director and leading stem cell researcher, Professor Clare Parish, will co-lead the project’s
Professor Clare Parish
preclinical research, including studies to test the safety and effectiveness of using lab-grown dopamine-releasing neurons, alongside researchers from the University of Sydney. “By restoring dopamine in the brain that is lost as a result of Parkinson’s disease, we are confident we will be able to not only halt progression but also modify the disease in a targeted way to reverse the damage,” Professor Parish said. “In effect, we are aiming to turn back the clock on Parkinson’s and give people living with the disease the movement and brain function they have lost, hallmarks of the disease which have profound effects on their lives.” The final stage of the program will be a clinical trial at the Royal Melbourne Hospital led by Associate Professor Andrew Evans, Director of the Movement Disorders Service, with expansion to the Alfred Hospital.
Associate Professor Evans previously led the world’s first Phase I clinical trial of stem cell therapy for Parkinson’s disease and will lead the first-in-human study in this program. “This will be one of the first clinical trials to test whether a hypoimmune neural cell therapy, which is specifically engineered to evade the immune system, can survive and function without the need for longterm immunosuppression,” Associate Professor Evans said. If successful, the approach could support a one-time, diseasemodifying treatment for Parkinson’s disease – something not achievable with current therapies, which only manage symptoms. Parkinson’s disease is the fastestgrowing neurological disease globally, affecting more than 200,000 Australians and 10 million people worldwide.
Specialist labs typically grow stem cells from donated blood or skin cells. These lab-grown cells can then be turned into almost any cell type in the human body and are known as induced pluripotent stem cells (iPSCs). Replacement cells often come from healthy donors and can be used in multiple patients. This “one-for-many” approach is referred to as allogeneic therapy. A second approach involves taking cells directly from the patient, modifying them and reintroducing them to the patient. This is a “onefor-one” approach, known as autologous therapy. This method is more expensive and requires
extensive oversight. Moreover, the patient’s own cells may still carry disease-causing mutations, which can limit effectiveness. For these reasons, the first approach is often preferable. But a major challenge is immune rejection. Because the transplanted cells are not the patient’s own, the body may treat them as foreign and reject them. The Florey has developed strategies to overcome this by effectively providing transplanted cells with an “invisibility cloak”. Although these cells are allogeneic, this modification helps them evade detection by the recipient’s immune system, reducing the likelihood of rejection.
Explainer
What is stem cell therapy? The human body is made up of trillions of cells. When disease strikes, cells can be damaged or die. Stem cell therapy is an innovative approach using healthy cells to replace those lost to disease. Stem cell therapy aims to alter the course of a disease by stopping progression and potentially restoring function. By replacing lost cells, the aim is to restore activity in a specific tissue or organ.
Brain Matters Spring 2026
3
MS ‘mini brains’ provide new hope Dr Samantha Barton and Dr Shwathy Ramesan
Florey researchers are developing 3D ‘mini brains’ they hope will help speed up the search for much-needed drug treatments for multiple sclerosis (MS), an autoimmune condition affecting almost three million people worldwide. Led by Dr Samantha Barton from The Florey’s Myelin in Health and Disease Group, the team is using reprogrammed adult stem cells to engineer a human-like central nervous system cell model the size of a grain of rice. Dr Barton recently received a MS Australia grant, allowing her team to investigate how the brain naturally produces myelin.
Myelin is a fatty sheath that covers and protects nerve fibres and allows messages, via electrical impulses, to travel quickly around the brain, spinal cord and the rest of the body. In MS, the immune system mistakenly attacks myelin, causing nerve damage, neurological symptoms and, over time, disability. MS Australia Deputy Head of Research Dr Fiona McKay said the project addressed the top research priority identified by people affected by MS. “When we asked people affected by MS which research areas mattered most to them, repair and regeneration emerged as the top priority,” Dr McKay said. “Research like Dr Barton’s is
improving our understanding of how myelin forms and how it may one day be repaired.” There are currently no therapies that repair this damage or prevent disability. Existing MS medications only treat symptoms and slow progression. Dr Barton and her team are also continuing to develop their cell models, which would be a significant step forward in MS research. “In science, we typically use animals to model diseases for research, but drugs identified to work in animal models of disease are rarely effective in people, so creating more human-relevant model systems is important,” Dr Barton said. “The relevance of our new system
Back the Brain – and be part of what’s next Brain and mental health conditions are now the leading cause of ill health and disability worldwide, affecting more than one in three people. Almost all of us know someone. That’s why we’re launching Back the Brain: a community for people who believe the future of brain health starts with research. For more than 50 years, The Florey has worked to prevent, treat and reduce the burden of these conditions 4
Brain Matters Spring 2026
across the lifespan – from dementia and depression to stroke and alcohol use disorder. But as they become more common, discovery needs more people behind it. Back the Brain is built around three things you can do:
Learn how your brain works and what keeps it healthy, from the scientists who study it. Support the research that matters most to you. Advocate for brain health to become a national priority.
would be unparalleled. Building on our previous experiments which have shown that we can generate myelin in the model system, we will go one step further with the introduction of immune cells to trigger injury similar to MS to study remyelination. “This highly sophisticated model could help researchers better understand what drives myelin damage and repair in MS and would give us a new platform to screen potential new drugs that protect or restore myelin. “The dream is to find new ways to slow or prevent MS progression – we hope our models could help us do that.” Working with Dr Barton, Florey post-doctoral fellow, Dr Shwathy Ramesan, said a MS cell model would be a gamechanger because it would allow researchers to see drugs working in near real time on human cells. “We believe we are closer than ever to creating the best possible platform for MS drug development with the aim of potentially reversing the disease and giving quality health back to people living with MS,” Dr Ramesan said. The project is also supported by the CASS Foundation, the Rebecca L. Cooper Medical Research Foundation and a National Health and Medical Research Council Ideas grant.
You’ll see more about Back the Brain over the coming months, on our website, in your inbox and at our events. Joining will be free, and we’d love you to be part of it from the start. Back the Brain. Back the future.
Dr Sonali Reisinger
Gut-brain link in NF1 A Florey study suggests therapies targeting gut bacteria could in future help people with an inherited condition who have learning and behavioural difficulties, including autism and ADHD. While one in 3000 people are born with neurofibromatosis type 1 (NF1), the severity of physical and cognitive symptoms varies greatly between those affected. In many cases, NF1 is associated with learning, thinking and behavioural difficulties, anxiety and depression. More than a third of children with NF1 have autism and about four in 10 have ADHD. In findings published in Molecular Psychiatry, Florey researchers uncovered significant changes in gut microbiota in a NF1 mouse model compared to mice without the NF1 gene mutation, suggesting a potential link between the gut and brain in NF1. Lead researcher Dr Sonali Reisinger said the study was the first to investigate and find a possible connection between gut bacteria and brain-related symptoms of NF1. “Our NF1 mice displayed differences in their cognition and behaviour compared to mice without NF1. They also had larger brains, a common feature of people with NF1,” Dr Reisinger said. “Crucially, we also observed changes in their gut bacteria which suggests gut microbiota could be an important new area to study for NF1.”
In male mice in particular, certain groups of bacteria were changed in ways that partly overlap with findings from clinical and preclinical autism research. Head of The Florey’s Epigenetics and Neural Plasticity Group, Professor Anthony Hannan, said this new discovery from his team identified the gut-brain axis as a novel therapeutic target for NF1. “Recent research has focused on whether bacteria in the gut might be involved in brain conditions, but this has not been studied in NF1 until now,” Professor Hannan said. “Our new findings add to mounting evidence about the connection between the brain and gut. If we can replicate this study in humans, it paves the way for potential new therapies to help people living with NF1related cognitive and behavioural difficulties, including autism and ADHD.” The research was supported by a research funding grant from the Flicker of Hope Foundation, established in 2018 to raise funds for medical research into neurofibromatosis. The charity directs 100 per cent of donations to research. Brain Matters Spring 2026
5
Vale Neale Daniher AO
It was with deep sadness that The Florey mourned the passing of FightMND co-founder and former Australian of the Year, Neale Daniher AO. Neale was an extraordinary ambassador and tireless advocate in the fight against “the Beast” that is motor neurone disease (MND), which he courageously lived with for more than a decade. Through his powerful advocacy work, Neale helped to raise millions of dollars for researchers in Australia and around the world working to find a cure for MND. For more than a decade, this funding has provided critical support for Florey researchers to think innovatively, use cutting-edge technology, and help to improve the lives of people affected by what is one of the most complex neurological disorders. Professor Peter van Wijngaarden, Executive Director of The Florey, said: “Neale was both a dear friend of The Florey and a great source of inspiration. “Neale made the fight against MND one that everyone can get behind. He created a movement that so many are proud to be a part of. An extraordinary $17.5 million has been awarded to The Florey from FightMND, enabling us to be bolder than ever in our search for a treatment. “Even in his own battle with MND, Neale was fighting for everyone who would come after him. We will forever be grateful to him and FightMND for putting this disease in the spotlight, inspiring so many and supporting vital research at The Florey and across the globe.” Dr Thanuja Dharmadasa, The Florey’s leading MND clinician-researcher, said: “When I first started seeing patients with MND, it was an area of medicine where there was very little hope to offer. In founding FightMND, Neale fundamentally changed that. “There is no doubt that Neale has made Australia a global leader in MND research. The support and momentum that he created has given us the ability to 6
Brain Matters Spring 2026
think outside the box and pursue bold new approaches to solve this complex disease. His legacy extends far beyond research funding; he has changed the national conversation around MND both in the clinic and in the broader community. “Neale was deeply engaged in the progress of MND research and participated in studies aimed at improving outcomes for people living with the disease. He understood the urgency and the challenge of the work ahead; his involvement has brought great hope to those living with MND and tremendous motivation to the scientists striving to make a difference.” “Neale’s advocacy and relentless determination have mobilised the nation. It is this powerful combination of advocacy and hope founded in research that will stand as Neale’s enduring gift,” Professor van Wijngaarden added.
MND researcher-clinician Dr Thanuja Dharmadasa
Can diet lower MS risk? Florey research has found a potential link between a Mediterraneanstyle diet and a lower risk of MS onset, with a key epigenetic process playing a partial mediating role. Dietary intake has previously been linked to MS onset risk, but the mechanism influencing this link has been unclear. Florey researchers have investigated whether differences in DNA methylation — a biological process that helps control whether genes are turned on — could help explain part of the link between diet and MS risk. They also studied whether these diet–MS relationships were different in people with key MS-related genetic risk variants. MS is a chronic disease in which the immune system attacks the brain and spinal cord. Using data collected from more than 500 participants in the Australian Ausimmune Study, the researchers showed up to one third of the association between consuming a Mediterranean-style diet and lower MS onset risk was mediated by differential DNA methylation. The study, published in the journal Multiple Sclerosis, also found the relationship between a Mediterranean-style diet and a lower risk of MS onset appeared to apply even in people who carried common genetic variants that are associated with increased risk of MS. Participants’ typical dietary intake was scored on how well it aligned with the Mediterranean diet. Using their blood samples, researchers then measured DNA methylation. With these measures, they evaluated the associations of
Mediterranean-style diet with MS risk and how much of this acted via differences in DNA methylation in particular sets of genes. Lead researcher and Florey PhD student, Mehari Merid, said the findings provide valuable insights into how diet may be acting upon MS onset risk. “Although this study does not provide new information for people to change their diets to manage the course of MS, it does emphasise the role of nutrition,” Mr Merid said. “Our work is important in understanding how diet and other risk factors may affect MS and informs future prevention and treatment strategies.” Co-author, Professor Anne-Louise Ponsonby, who heads The Florey’s Neuroepidemiology Research Group, said diet is an important area of study in MS. “If we understand how an apparent beneficial effect acts through epigenetic programming - switching a set of genes on or off - then we may be able to understand causes of MS onset better,” Professor Ponsonby said. “However, people with MS should continue to follow advice from their doctor and neurologist, alongside national dietary guidelines, when making dietary choices.” The project was supported by Multiple Sclerosis Australia, the National Health and Medical Research Council and the National Multiple Sclerosis Society in the United States.
Injecting new energy into Alzheimer’s disease research Alzheimer’s disease is the most common form of dementia, affecting more than 400,000 people in Australia. It is also a leading cause of death worldwide. Dr Francesca Alves, a Senior Research Fellow at The Florey, believes earlier diagnosis and more effective treatments are key to combating the disease as cases rise globally. To support her research exploring how the brain produces energy, Dr Alves has been awarded the Race Against Dementia Post-Doctoral Fellowship from the Dementia Australia Research Foundation. “In Alzheimer’s disease, brain cells struggle to produce enough energy to stay healthy and do their jobs properly,” Dr Alves said. “This energy failure may be a key reason why cells become damaged and die, leading to memory loss and other
symptoms. Yet most current treatments do not address this problem. “With this project we will develop a new brain scan that can measure energy production in the brain. If successful, it could also aid in early detection of Alzheimer’s disease. “The final part of the project will aim to develop and undertake laboratory tests of a new treatment for Alzheimer’s disease by delivering energy directly into brain cells.” Dr Alves is leading one of 23 new research projects worth a combined $4.5m funded by the Dementia Australia Research Foundation. Brain Matters Spring 2026
7
Future of Young Stroke Service uncertain
Young stroke survivor Ida Laino
Ten days after giving birth to her second child in 2024, Ida Laino suffered a stroke. At just 38, Ida showed no obvious signs of a stroke. It was only after she began forgetting basic information that a brain scan was conducted and doctors realised something was seriously wrong. “Faces became unrecognisable – I mistook my mother for my aunt – and my vision grew blurry. My short-term memory was gone; I couldn’t even remember having a second child,” Ida recalled. Every day, 13 young Australians aged 18 to 55 experience a stroke and many will live with the effects for decades. The impacts extend beyond their physical recovery, affecting their ability to work, care for families and adjust to changes in their daily lives. However, accessing age-appropriate services remains limited. The Young Stroke Service (YSS) helps address these gaps, building on years of research showing that too often, young stroke survivors struggle with their recovery due to unmet needs. YSS is currently supported by a Medical Research Future Fund grant through to the end of 2026, and efforts are underway to secure its long-term sustainability. Co-lead Investigator of YSS Professor Vincent Thijs said continued support is critical to ensure younger stroke survivors get the recovery they need.
Ida first heard about YSS from her rehabilitation team who encouraged her to give it a try. She went on to work with the service to set realistic goals for returning to work and managing her anxiety.
“ They’ve given me practical strategies and tailored support that have become an essential part of my daily routine.” Since 2023, YSS has supported more than 550 young Australians in Victoria and South Australia. “Young stroke is an increasing health concern, and this service is not a nice-to-have,” Professor Thijs said. “It delivers critical support to young stroke survivors at one of the most challenging times in their lives to help them rebuild their futures.”
“ Without ongoing funding, there is a real risk that younger stroke survivors will miss out.” Ida faced a daunting recovery, relearning to read and spell while caring for a newborn and toddler. “It broke my heart knowing that potentially ... I may not be able to read to my children ever again, or something as simple as going to a cafe and reading the menu,” she said. 8
Brain Matters Spring 2026
Professor Vincent Thijs
Conquering cancer one step at a time Brain cancer researchers from The Florey recently swapped their lab coats and pipettes for active wear and a baton – all for a good cause. They were among more than 600 people who took part in Conquer Cancer, a relay that ran for four consecutive weeks around Melbourne’s Princes Park in May, to raise money for The Florey and Camp Quality. Conquer Cancer was founded by Ben Jeffrey, whose father passed away from brain cancer when he was just a child, and his good friend Peter Christen. Professor Lucy Palmer, who leads brain cancer research at The Florey, and 15 others from her lab participated in the relay. “Brain cancer is unique, but we’re making new discoveries in the lab all the time. Every day brings us closer to new therapies for this devastating disease,” Professor Palmer said. Sam Combes, a PhD student from Professor Palmer’s lab, was among the top fundraisers. “Through my PhD research, I see firsthand how funding contributes to critical breakthroughs and better outcomes for patients and families,” Mr Combes said. “On a personal level, people in my family and close to me have been affected by cancer.” His research focuses on gliomas which are among the most aggressive, deadly and common brain cancers.
Florey PhD students Lena Kricsfalussy-Hrabár, Eleonora Regolo and Sam Combes
Florey Executive Director Peter van Wijngaarden
Olympic racewalker Jemima Montag
“Despite decades of research, patient survival has barely improved. One major reason is that we still treat these tumours as isolated masses of cancer cells. But we now know something fundamentally different – gliomas are actually integrated into brain circuits. “My research asks a simple but powerful question: What if brain activity itself is driving tumour growth – and what if we can interrupt that?”
Neuropix 2026 imaging competition Neuropix is our annual competition for microscopy images produced by Florey scientists. Here are this year’s winners. Fourth of July Scientific Award – Francois Beau, PhD student, Myelin in Health and Disease Group Using stem cells grown in the laboratory, this image recreates one of the earliest stages of human cortical development. The cells spontaneously organise into neural rosettes, revealing the remarkable capacity of human stem cells to build the earliest blueprint of the developing cortex.
The First Spark People’s Choice Award – Gabriella Farrell, PhD student, Stem Cells and Neural Repair Group This is an image of a lab-grown human mini-brain, in which we can see oligodendrocyte cell bodies (purple) as well as their projections (green and red).
Brain Matters Spring 2026
9
Dani and Ken Harris visiting The Florey’s sepsis research lab
Backing sepsis research: The Harris family’s story Ken Harris and his daughters, Dani and Katrina, are determined to spare other families the heartbreak of losing a loved one to sepsis. Their beloved wife and mother, Gillian Harris, sadly passed away in a Melbourne hospital after developing sepsis, an extreme reaction to infection. As well as being the much-loved centre of her extended family, Gillian is fondly remembered as a mentor, confidant, leader and friend. She had been a dedicated primary school teacher, managed the family’s engineering business and was president of Court Network, an organisation that she volunteered with for more than 30 years that supports people navigating the court system. Daughter Dani said her 78-year-old mother had been recovering well from bowel cancer surgery when she was admitted to hospital in May 2023. Gillian was being treated for a bacterial infection, following her first round of chemotherapy. “She was still bright and herself – sitting up in bed texting her family that everything would be fine,” Dani recalled. But two days later the Harris family’s world turned upside down. “I remember mum’s doctor calling me to say that I should come in,” Dani said. “Mum was very weak that day and could barely lift her arms to feed herself… her breathing was very shallow.” Within hours, Gillian was diagnosed with sepsis and was 10
Brain Matters Spring 2026
transferred to intensive care where she was intubated and placed in an induced coma. “We were stunned. We went into the hospital and sat with her, holding her hand and telling her to be strong, that she could beat this, praying she would pull through,” Dani said. Unfortunately, the grandmother of two had Gillian Harris suffered a massive stroke. “Mum’s body was beyond repair, her organs were shutting down and she would need a lifetime of medical support – if she ever left the hospital.” As per Gillian’s medical directive, the family made the difficult decision to withdraw life support. “I held her hand and told her she did not have to fight anymore,” Dani said. “That was the hardest day of my life.” When her father Ken read a newspaper article about The Florey’s research into sepsis after losing his adored wife, he decided to become a Florey donor. Dani said her “tough, strong, generous, intelligent and giving” mum would be proud. “I see this donation as a continuation of her life – giving help to others. I would hope our donation would be able to assist in clinical trials and into research to treat infection before it develops into sepsis.” The Florey’s Head of Stroke and Critical Care Research Priority Area, Professor Yugeesh Lankadeva, has codeveloped and patented sodium ascorbate as a novel therapy for sepsis. The megadose sodium ascorbate formulation is being tested at 12 hospitals across Australia as a potential treatment to reverse sepsis-induced multi-organ injury in critically ill patients treated in intensive care units. “With the Harris family’s generous support, now we are taking the next bold step: Can we prevent sepsis from developing at all? Instead of treating patients once organ failure has begun, we aim to intervene early in infection before sepsis takes hold.” Professor Lankadeva said.
A tribute to Dr Hugh David Niall AO 15 August 1937 – 11 April 2026
Dr Hugh Niall researching the molecular structure of the hormone relaxin
Dr Hugh Niall AO was a scientific figure of rare stature, whose influence on Australian biotechnology and on the translation of discovery science into medicines was both profound and enduring. It was at The Florey – then the Howard Florey Institute — that his impact on Australian science was most deeply felt. As our Associate Director, he helped shape the Institute during a formative period, contributing not only scientific leadership but a broader vision of what Australian biomedical research could be. His work on the cloning and synthesis of the hormone relaxin was a landmark achievement, but equally important was the culture of intellectual ambition and quiet excellence that he helped to foster. The Florey’s standing as a globally respected research institute owes much to figures such as Hugh, who set exacting standards while demonstrating that world-class science could be done here, in Australia, with confidence and originality. His subsequent career at Genentech in San Diego extended that influence onto the global stage. As VicePresident of Research Discovery, he played a central role in guiding programs that would lead to therapies now used worldwide, including Nutropin, Herceptin, Avastin and Lucentis. These medicines have transformed the treatment of cancer, growth disorders and eye diseases, and stand as a testament to Hugh’s ability to connect fundamental science with clinical impact. Yet his commitment to Australian science remained constant. Returning in the mid-1990s, he brought with him
international experience and a determination to strengthen the local biotechnology sector. At Biota Holdings, he forged a partnership with the Victorian College of Pharmacy, CSIRO and GlaxoWellcome that resulted in the development of Relenza, one of the first antiviral therapies for influenza and a defining achievement in Australia’s Dr Hugh David Niall AO emerging biotechnology industry. In later roles, including as Chairman of Avexa and Chief Executive of the Australian Stem Cell Centre, he continued to guide organisations through both scientific and strategic complexity, strengthening the sector as a whole. Across these endeavours, Hugh was not simply a participant in the development of modern biotechnology; he was one of its architects. He moved with equal authority between disciplines and between sectors, helping to build the pathways that link discovery to application. His contributions have had lasting impact, not only in the therapies that bear the imprint of his work, but in the institutions he helped shape. In recognition of these contributions, he was awarded his Doctor of Medical Science (honoris causa) from University of Melbourne in 2012 and was appointed an Officer of the Order of Australia in 2015. Dr Hugh Niall AO is survived by his children Lucy, Jake, Ben and Emma. Brain Matters Spring 2026
11
Sian’s gift in memory of her mother Florey donor and supporter Dr Sian Prior decided to become a bequester after the death of her mother Professor Margot Prior AO FASSA in 2020. Margot was a professor of psychology at the University of Melbourne, and her research career was primarily focused on autism, temperament and literacy development. She was also former director of psychology at the Royal Children’s Hospital and adjunct professor at La Trobe University. A wing of Latrobe University’s Olga Tennison Autism Research Centre (OTARC) has been named after Margot, in recognition of her pioneering work which continues to benefit countless young people. Margot developed dementia symptoms in her seventies and was eventually diagnosed with Alzheimer’s disease, a particularly cruel brain disorder for someone with such a brilliant mind. When Sian discovered that Florey researchers were doing pioneering research into the diagnosis and treatment of Alzheimer’s disease, including The Florey in her Will seemed a perfect way to honour her mother’s legacy. “Our mother was a fierce advocate for and practitioner
Margot Prior celebrating her 80th birthday with daughters Sian and Yoni
of evidence-based scientific research. For example, she initiated an Australian longitudinal study on temperament that has provided four decades of vital data for psychology researchers,” Sian said. “I’ve always worked in creative fields, never in the sciences, but I’m sure Margot would be happy that her youngest daughter had found a way to follow in her footsteps in supporting the pursuit of scientific knowledge.”
Consider leaving a gift in your Will in memory of someone special in your life. To request our Gifts in Wills guide or to speak to us about your wishes, please contact our Gifts in Will Manager, Nola Wilmot, on 03 9035 9710 or email philanthropy@florey.edu.au By letting us know you have included The Florey in your Will, you can be involved in Florey Society events.
The Florey Society at the June boardroom briefing
How brain cells ‘talk’ to each other The Florey Society met in June to hear from Associate Professor Laura Vella, head of The Florey’s Extracellular Vesicle Group, about cellular communication. Associate Professor Vella has spent the past 20 years understanding how cells talk to one another including in Alzheimer’s, Parkinson’s and prion diseases. 12
Brain Matters Spring 2026
She describes extracellular vesicles as “bubbles that deliver messages between cells.” Because these bubbles carry information from brain cells, they offer a simple way to gain insight into what is happening in the brain without needing to look directly at brain tissue. “By analysing the molecular signals carried by these tiny bubbles we begin to see improvements in the speed of prion disease diagnosis and gain insights into diseaserelated changes in Parkinson’s disease,” Associate Professor Vella said.